24.04.2020 Aker Daily Analysis

24.04.2020 Aker Daily Analysis

Aker Biosciences today is trading at $3.62, it went up with $0.02 from $3.62 This is mainly because the deal between Akers Biosciences and Premas Biotech is already starting to show promise. The companies are working together to find a vaccine to treat coronavirus by using Aker’s expertise to navigate the regulatory hurdles in order to expedite the process. The company announced early April that they had successfully acquired clones of three coronavirus antigens they are using to develop the vaccine, now the companies must successfully complete purification and post-expression processing before being allowed to launch tests on humans. According to Aker’s Executive Chairman Christopher Schreiber, there should be an update later at the end of April concerning the "second stage in protein expression." This information is, therefore, giving the investors hope hence the rise of the share today.